AbbVie Nears $10.9B Acquisition of Apogee Therapeutics
AbbVie is reportedly close to a $10.9 billion deal to acquire Apogee Therapeutics, a move that would significantly expand its immunology pipeline.
AbbVie is nearing a $10.9 billion agreement to acquire Apogee Therapeutics, according to reports, in what would rank among the pharmaceutical giant's largest acquisitions in recent years. The deal, if completed, would hand AbbVie a significant expansion of its immunology and inflammation drug pipeline at a critical moment as the company works to offset revenue pressure from biosimilar competition facing its blockbuster drug Humira.
Apogee Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for atopic dermatitis and other inflammatory conditions, areas where AbbVie already holds a strong commercial presence. Adding Apogee's experimental portfolio would deepen AbbVie's bench of next-generation biologics as it competes aggressively in the immunology space against rivals including Eli Lilly and Sanofi.
Read more Pudgy Penguins Trading Cards Land in Target Stores Nationwide →
The reported $10.9 billion price tag reflects the premium investors and acquirers have been willing to pay for late-stage or differentiated immunology assets, a sector that has seen intense deal activity across the biopharma industry. For AbbVie, whose Skyrizi and Rinvoq franchises have shown strong growth, bolting on a promising clinical-stage platform could accelerate its post-Humira transition strategy.
No official confirmation from either company had been issued at the time of reporting, and deal terms could still change or fall through entirely. Investors and analysts will be watching closely for any formal announcement, which could reshape competitive dynamics in the atopic dermatitis treatment landscape.
Continue reading at SeekingAlpha.
